About Us Our Values

John Evans joined Beam in 2017 as CEO, bringing significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry.

Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. At Agios, Mr. Evans served as IDH Portfolio Executive, providing strategic and operational leadership for a portfolio of first-in-class IDH inhibitors including IDHIFA and TIBSOVO. He helped initiate and lead Agios’ landmark alliance with Celgene, resulting in over $600M of funding and investments across multiple research collaborations in cancer metabolism. He also co-led Agios’s expansion into rare genetic diseases. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company (Pharmaceuticals practice) and MedImmune.

Mr. Evans holds an M.B.A. in Healthcare Management from Wharton, a Masters in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.

Dr. Giuseppe Ciaramella is the President of Beam Therapeutics. Dr. Ciaramella has more than 20 years of drug discovery experience at Moderna, AstraZeneca, Boehringer Ingelheim, Pfizer and Merck.

Throughout his career he has held several leadership roles, with a particular focus in the fields of antivirals, immunology and biotherapeutics. Prior to joining Beam Therapeutics, Dr. Ciaramella was the CSO of the Infectious Diseases division of Moderna Therapeutics, where he was instrumental in generating some of the first mRNA vaccines to be dosed in humans, several of which are progressing through clinical studies. At Boehringer Ingelheim, he served as Vice President and Head of Collaborative Research where he had responsibility for external R&D and was a member of the Research Leadership Team. Prior to Boehringer Ingelheim, he spent 14 years at Pfizer in the UK where he held several Discovery leadership positions, including head of Biotherapeutics, head of Antivirals and head of Lead Discovery.

He has contributed to several clinical candidates, both small molecule and biologics and to the anti-HIV drug Maraviroc (Selzentry TM), which won the USA Prix Galien for Best Pharmaceutical in 2008. He is a member of the Infectious Diseases Society of America (IDSA) and of the American Society of Gene Therapy (ASGT).

Dr. Ciaramella holds a Ph.D. in Biochemistry and Molecular Biology from University College London.

Dr. Gopi Shanker is the Chief Scientific Officer of Beam Therapeutics. Dr. Shanker has more than two decades of broad drug discovery experience at Novartis, Amgen and Regeneron ranging from developing target concepts to advancing molecules through clinical development. He has contributed to the development of several clinical candidates and to the migraine drug, Aimovig®. With a strong background across multiple drug modalities including small molecules, biologics and gene therapies, he will bring great experience and leadership to our R&D teams. Dr. Shanker has a proven ability in successfully building, coaching, and developing cross-functional drug discovery teams as well as creating purpose-driven, highly productive research organizations. He is passionate about mentoring individuals and teams towards having high impact.

Dr. Shanker joins us after leading Tevard Biosciences, and prior to that, he was with Novartis Institute of Biomedical Research and during his tenure at Novartis, he held multiple key leadership roles including Head of Neuroscience Disease Area, Head of Psychiatry and Neurodevelopmental Disorders, and Head, Ion Channels and Receptors.

Dr. Shanker holds a Ph.D. in Biochemistry from Indian Institute of Science, Bangalore, India, a M.Sc in Biotechnology from Madurai Kamaraj University, India, and a B.Sc in Microbiology from Osmania University, India.

Terry-Ann Burrell is Chief Financial Officer of Beam. Prior to Beam, Ms. Burrell spent 11 years with J.P. Morgan, most recently as a Managing Director in the healthcare investment banking group. There, she had broad coverage across the biotechnology and pharmaceutical industries, helping to execute over $10 billion in equity and equity linked financings and more than $50 billion in M&A transactions. She was instrumental in advising clients on transaction considerations, including strategic rationale, valuation and structuring, and engaged with more than 100 companies during her tenure. Prior to J.P. Morgan, Ms. Burrell worked in equity research at Citigroup, where she covered specialty pharmaceuticals and generics.

Ms. Burrell holds an MBA from New York University Leonard N. Stern School of Business and a B.A. from Harvard University.

Amy Simon, M.D. is Chief Medical Officer of Beam. Dr. Simon brings more than 20 years of clinical experience to Beam, serving in roles as a physician-scientist in academia and the biotechnology industry.

Dr. Simon joins Beam from Alnylam Pharmaceuticals, where she spent over a decade in various roles with increasing responsibility for the clinical development of RNAi-based medicines, most recently serving as Vice President, Clinical Development. During her tenure at Alnylam, she led the successful execution of clinical programs from natural history studies to Phase 1 through Phase 4 studies, regulatory interactions with both U.S. and ex-U.S. authorities, and drug approvals in the U.S. and EU. Dr. Simon was the lead clinician developing GIVLAARI^® (givosiran) for patients with acute hepatic porphyria, which was approved by the Food and Drug Administration in 2019. Prior to entering the biotech industry, Dr. Simon worked in academia at Tufts University, serving as a professor and a director of the Asthma Center in the Pulmonary and Critical Care Division at Tufts University School of Medicine and as a professor at Tufts Graduate School of Biomedical Science where her laboratory conducted basic science research on asthma. She began her career in clinical practice, training as a resident in internal medicine and as a fellow in pulmonary and critical care medicine at Tufts Medical Center.

Dr. Simon holds a B.A. in History and Science from Harvard University, and an M.D. from Tufts University School of Medicine.

Courtney Wallace is Chief Business Officer of Beam Therapeutics. Ms. Wallace previously served as Senior Vice President, Business Development and Strategy and has served as Beam’s head of corporate strategy and business development since 2018. She was previously a Senior Director of Business Development at Celgene Corporation, where she was responsible for leading collaborations, licensing transactions, equity investments, and mergers and acquisitions across a variety of therapeutic areas. Prior to joining Celgene, Ms. Wallace was a consultant with Easton Associates (now part of Navigant Consulting), a boutique healthcare management consultancy. While with Easton, she advised clients on general corporate strategy, pipeline and portfolio planning, clinical development, sales and marketing activities, and business development.

Ms. Wallace holds an A.B. from Harvard College and an MBA from Harvard Business School.

Susan O’Connor is an accomplished executive with progressive and diversified experience in the biotechnology sector. With more than 25 years of experience in human resources, she has made significant contributions in building and leading companies from the initial startup phase and scaling through commercialization. Her expertise includes overall talent management, culture building, strategic recruitment and selection, IPO planning and execution, leadership development as well as board development and engagement. Prior to Beam, Ms. O’Connor launched O’Connor & Associates, a strategic human resources consulting firm, in 2008. She has partnered with several venture capital firms, including Third Rock Ventures, acting as the chief human resources executive for a number of biotech companies, including Celsius Therapeutics, Relay Therapeutics, Blueprint Medicines, Voyager Therapeutics and Fulcrum Therapeutics, among others. Prior to launching O’Connor & Associates, Ms. O’Connor was vice president, human resources at Johnson & Johnson, where she also served as a board member for several operating companies within the medical devices sector of the company.

Ms. O’Connor holds a bachelor’s degree from Providence College.

Dr. Christine Bellon is Chief Legal Officer of Beam Therapeutics. She brings to Beam more than 25 years of experience in the life science industry. Prior to joining Beam, she served as Senior Vice President, General Counsel and Corporate Secretary for Forma Therapeutics, where she built and led a legal team, negotiated changes to the company’s operating structure, and played a key role in negotiations with Forma’s strategic partner. Prior to Forma, Dr. Bellon was Senior Vice President of Legal Affairs for Relay Therapeutics, where she helped obtain foundational partnerships for the company and formulated its intellectual property strategy. Prior to Relay, she served as Vice President of Legal Affairs and Corporate Secretary at Blueprint Medicines, where she was instrumental in building its global IP portfolio, securing strategic partnerships and executing its initial public offering. Earlier in her career, Dr. Bellon practiced law and served in legal leadership roles at Hydra Biosciences and Infinity Pharmaceuticals.

Dr. Bellon holds a B.S. in Chemistry from Yale University; a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology, where she did research in the laboratory of K. Barry Sharpless; and a J.D. from Columbia Law School. She is a trustee of the Boston Museum of Science.

Suzanne Fleming is Chief Accounting Officer at Beam Therapeutics. Ms. Fleming has more than 25 years of experience in finance leadership roles in the life science industry. Prior to joining Beam Therapeutics, Ms. Fleming served most recently as Senior Vice President, Finance and Treasurer at Epizyme, Inc., where she was responsible for all finance and accounting functions. Before Epizyme, she was Vice President, Finance at Foundation Medicine, where she worked closely with Roche after their purchase of a majority stake in the company. Ms. Fleming also held senior finance positions at Aegerion Pharmaceuticals, AVEO Pharmaceuticals, Transform Pharmaceuticals and Transkaryotic Therapies.

Ms. Fleming holds a B.S. degree in Accounting from Stonehill College and earned her CPA in Massachusetts.

Brian Riley, an experienced leader in operations, quality and manufacturing, is Chief Manufacturing Officer at Beam. Prior to Beam, Mr. Riley spent five years at Catalent Pharma Solutions, initially as General Manager, Biologics and most recently as the Vice President of Operations. There, he helped to cultivate the company’s biologics business, managing five biologics plants supporting the company’s drug substance and products across North America and Europe. Prior to Catalent, Mr. Riley served as the Site Director of Durham, NC operations at bioMerieux, where he led both the company’s compliance remediation effort and global growth platform. Before bioMerieux, Mr. Riley held progressive roles through quality and operations at Biogen Idec, Amgen and Diosynth Biotechnology.

Mr. Riley holds an MBA from Campbell University and a B.S. from North Carolina State University.

Dr. Manmohan Singh is the Chief Technology Officer at Beam Therapeutics. Dr. Singh has more than 24 years of drug discovery and development experience at Takeda Pharmaceuticals, Novartis and Chiron Corporation.

Prior to joining Beam Therapeutics, Dr. Singh was the Global Head of Drug Product Development at Takeda Vaccines, where he oversaw the drug product development of all vaccine programs, including Takeda’s dengue vaccine that was in Phase III efficacy study. At Novartis, he served as the Head of Formulation Development for more than 10 years and was instrumental in the licensure of several key vaccines (Bexsero , Fluad, Flucelvax) that were subsequently divested to GSK and CSL. He also led the development of the LNP platform of Novartis’s RNA vaccine. Prior to Novartis, Dr. Singh also spent more than 10 years at Chiron Corporation, where he led the development of Novel adjuvants and delivery systems for vaccines.

Based on his contributions at Chiron and Novartis, Dr. Singh is considered as one of the leading experts in the field of adjuvants and vaccine delivery systems. He has authored six books in this field and has more than 120 publications. He was elected as a Fellow of the American Association of Pharmaceutical Scientists (AAPS) in 2011.

Dr. Singh holds a Ph.D. in Pharmaceutics and Drug Delivery from the National Institute of Immunology in New Delhi, India.

John Lo, Ph.D., is chief commercial officer of Beam, where he is responsible for commercial readiness as well as leading product and portfolio strategy of a rapidly maturing and expanding portfolio.  Dr. Lo joins Beam after serving as an advisor to multiple private and public stage biotechnology companies including Beam.  Dr. Lo has held a number of global strategic and operating roles of increasing responsibility within the biopharmaceutical industry, as senior vice president, worldwide hematology at Bristol Myers Squibb, head of global marketing and market access at Astra Zeneca, corporate vice president, hematology and oncology at Celgene, and multiple P&L roles at Novartis.  While at these companies, Dr. Lo has successfully launched numerous drugs in the US and globally, including Tagrisso in lung cancer and two cell therapies.  Dr. Lo has also helped build strategies and grow R&D pipelines as co-chair of the Development Committee at Celgene, leading to multiple pivotal study investments.  Dr. Lo also spent several years as an associate principal at McKinsey & Company and holds a Ph.D. in molecular biology from MIT.